254 related articles for article (PubMed ID: 29721094)
1. Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers.
Gao RW; Teraphongphom N; de Boer E; van den Berg NS; Divi V; Kaplan MJ; Oberhelman NJ; Hong SS; Capes E; Colevas AD; Warram JM; Rosenthal EL
Theranostics; 2018; 8(9):2488-2495. PubMed ID: 29721094
[No Abstract] [Full Text] [Related]
2. Optimal Dosing Strategy for Fluorescence-Guided Surgery with Panitumumab-IRDye800CW in Head and Neck Cancer.
Nishio N; van den Berg NS; van Keulen S; Martin BA; Fakurnejad S; Zhou Q; Lu G; Chirita SU; Kaplan MJ; Divi V; Colevas AD; Rosenthal EL
Mol Imaging Biol; 2020 Feb; 22(1):156-164. PubMed ID: 31054001
[TBL] [Abstract][Full Text] [Related]
3. Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma.
Day KE; Sweeny L; Kulbersh B; Zinn KR; Rosenthal EL
Mol Imaging Biol; 2013 Dec; 15(6):722-9. PubMed ID: 23715932
[TBL] [Abstract][Full Text] [Related]
4. Tumour-specific fluorescence-guided surgery for pancreatic cancer using panitumumab-IRDye800CW: a phase 1 single-centre, open-label, single-arm, dose-escalation study.
Lu G; van den Berg NS; Martin BA; Nishio N; Hart ZP; van Keulen S; Fakurnejad S; Chirita SU; Raymundo RC; Yi G; Zhou Q; Fisher GA; Rosenthal EL; Poultsides GA
Lancet Gastroenterol Hepatol; 2020 Aug; 5(8):753-764. PubMed ID: 32416764
[TBL] [Abstract][Full Text] [Related]
5. Safety and Stability of Antibody-Dye Conjugate in Optical Molecular Imaging.
Pei J; Juniper G; van den Berg NS; Nisho N; Broadt T; Welch AR; Yi GS; Raymundo RC; Chirita SU; Lu G; Krishnan G; Lee YJ; Kapoor S; Zhou Q; Colevas AD; Lui NS; Poultsides GA; Li G; Zinn KR; Rosenthal EL
Mol Imaging Biol; 2021 Feb; 23(1):109-116. PubMed ID: 32880818
[TBL] [Abstract][Full Text] [Related]
6. Effect of Formalin Fixation for Near-Infrared Fluorescence Imaging with an Antibody-Dye Conjugate in Head and Neck Cancer Patients.
Kapoor S; Lu G; van den Berg NS; Krishnan G; Pei J; Zhou Q; Martin BA; Baik FM; Rosenthal EL; Nishio N
Mol Imaging Biol; 2021 Apr; 23(2):270-276. PubMed ID: 33078373
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity and Specificity of Cetuximab-IRDye800CW to Identify Regional Metastatic Disease in Head and Neck Cancer.
Rosenthal EL; Moore LS; Tipirneni K; de Boer E; Stevens TM; Hartman YE; Carroll WR; Zinn KR; Warram JM
Clin Cancer Res; 2017 Aug; 23(16):4744-4752. PubMed ID: 28446503
[No Abstract] [Full Text] [Related]
8. Fluorescence-guided imaging for resection margin evaluation in head and neck cancer patients using cetuximab-800CW: A quantitative dose-escalation study.
Voskuil FJ; de Jongh SJ; Hooghiemstra WTR; Linssen MD; Steinkamp PJ; de Visscher SAHJ; Schepman KP; Elias SG; Meersma GJ; Jonker PKC; Doff JJ; Jorritsma-Smit A; Nagengast WB; van der Vegt B; Robinson DJ; van Dam GM; Witjes MJH
Theranostics; 2020; 10(9):3994-4005. PubMed ID: 32226534
[TBL] [Abstract][Full Text] [Related]
9. The Sentinel Margin: Intraoperative
van Keulen S; Nishio N; Birkeland A; Fakurnejad S; Martin B; Forouzanfar T; Cunanan K; Colevas AD; S van den Berg N; Rosenthal E
Clin Cancer Res; 2019 Aug; 25(15):4656-4662. PubMed ID: 31142505
[TBL] [Abstract][Full Text] [Related]
10. Panitumumab-IRDye800CW for Fluorescence-Guided Surgical Resection of Colorectal Cancer.
Marston JC; Kennedy GD; Lapi SE; Hartman YE; Richardson MT; Modi HM; Warram JM
J Surg Res; 2019 Jul; 239():44-51. PubMed ID: 30798171
[TBL] [Abstract][Full Text] [Related]
11. Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer.
Rosenthal EL; Warram JM; de Boer E; Chung TK; Korb ML; Brandwein-Gensler M; Strong TV; Schmalbach CE; Morlandt AB; Agarwal G; Hartman YE; Carroll WR; Richman JS; Clemons LK; Nabell LM; Zinn KR
Clin Cancer Res; 2015 Aug; 21(16):3658-66. PubMed ID: 25904751
[TBL] [Abstract][Full Text] [Related]
12. Metastatic and sentinel lymph node mapping using intravenously delivered Panitumumab-IRDye800CW.
Krishnan G; van den Berg NS; Nishio N; Juniper G; Pei J; Zhou Q; Lu G; Lee YJ; Ramos K; Iagaru AH; Baik FM; Colevas AD; Martin BA; Rosenthal EL
Theranostics; 2021; 11(15):7188-7198. PubMed ID: 34158844
[No Abstract] [Full Text] [Related]
13. Different Toxicity of Cetuximab and Panitumumab in Metastatic Colorectal Cancer Treatment: A Systematic Review and Meta-Analysis.
Petrelli F; Ardito R; Ghidini A; Zaniboni A; Ghidini M; Barni S; Tomasello G
Oncology; 2018; 94(4):191-199. PubMed ID: 29393280
[TBL] [Abstract][Full Text] [Related]
14. Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study.
Dote S; Itakura S; Kamei K; Hira D; Noda S; Kobayashi Y; Terada T
BMC Cancer; 2018 Oct; 18(1):957. PubMed ID: 30290786
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and meta-analysis of the risk of severe and life-threatening thromboembolism in cancer patients receiving anti-EGFR monoclonal antibodies (cetuximab or panitumumab).
Miroddi M; Sterrantino C; Simmonds M; Caridi L; Calapai G; Phillips RS; Stewart LA
Int J Cancer; 2016 Nov; 139(10):2370-80. PubMed ID: 27450994
[TBL] [Abstract][Full Text] [Related]
16. Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
Juric D; Dienstmann R; Cervantes A; Hidalgo M; Messersmith W; Blumenschein GR; Tabernero J; Roda D; Calles A; Jimeno A; Wang X; Bohórquez SS; Leddy C; Littman C; Kapp AV; Shames DS; Penuel E; Amler LC; Pirzkall A; Baselga J
Clin Cancer Res; 2015 Jun; 21(11):2462-70. PubMed ID: 26034219
[TBL] [Abstract][Full Text] [Related]
17. A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial).
Akiyoshi K; Hamaguchi T; Yoshimura K; Takahashi N; Honma Y; Iwasa S; Takashima A; Kato K; Yamada Y; Onodera H; Takeshita S; Yasui H; Sakai G; Akatsuka S; Ogawa K; Horita Y; Nagai Y; Shimada Y
Clin Colorectal Cancer; 2018 Mar; 17(1):e83-e89. PubMed ID: 29169974
[TBL] [Abstract][Full Text] [Related]
18. Effects of an Unlabeled Loading Dose on Tumor-Specific Uptake of a Fluorescently Labeled Antibody for Optical Surgical Navigation.
Moore LS; Rosenthal EL; de Boer E; Prince AC; Patel N; Richman JM; Morlandt AB; Carroll WR; Zinn KR; Warram JM
Mol Imaging Biol; 2017 Aug; 19(4):610-616. PubMed ID: 27830425
[TBL] [Abstract][Full Text] [Related]
19. Use of panitumumab-IRDye800 to image microscopic head and neck cancer in an orthotopic surgical model.
Heath CH; Deep NL; Sweeny L; Zinn KR; Rosenthal EL
Ann Surg Oncol; 2012 Nov; 19(12):3879-87. PubMed ID: 22669455
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic antibody improves melanoma detection by fluorescently labeled therapeutic antibodies.
Sweeny L; Prince A; Patel N; Moore LS; Rosenthal EL; Hughley BB; Warram JM
Laryngoscope; 2016 Dec; 126(12):E387-E395. PubMed ID: 27576611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
